Lipid-lowering therapy and renin-angiotensin-aldosterone system inhibitors in the era of the COVID-19 pandemic

Katsiki, Niki; Banach, Maciej; Mikhailidis, Dimitri P.

doi:10.5114/aoms.2020.94503

Cited by 79 publications

(102 citation statements)

References 60 publications

Supporting

Mentioning

101

Contrasting

Order By: Relevance

“…In some cases, either discontinuation of statin therapy or continuation with caution and at lower doses is possible options [ 49 ]. Nonetheless, when statin discontinuation is required, other lipid-lowering therapies could be considered, especially in patients at high CVD risk, which are more prone to undergo COVID-19 complications [ 49 , 50 ].…”

mentioning

confidence: 99%

Commentary: Statins, COVID-19, and coronary artery disease: killing two birds with one stone

et al. 2020

Self Cite

View full text Add to dashboard Cite

mentioning

confidence: 99%

Commentary: Statins, COVID-19, and coronary artery disease: killing two birds with one stone

et al. 2020

Self Cite

View full text Add to dashboard Cite

“…Although the above reported in vitro data suggest an essential role of lipid rafts and cholesterol in viral entry, speci c con rmation in vivo is needed. In this context, these previous studies seemingly indicated the important role of statins therapy in preventing cellular entry of coronavirus can guide new therapies that may be directed SARS-CoV-2 [28]. However, to the best of my knowledge, there has been almost no evidence on the use of statins in patients with SARS-CoV-2.…”

Section: Discussionmentioning

confidence: 99%

“…We just found that patients from Chengdu cohort with the lipid-lowering pharmacological intervention was likely to the ICU admission (p = 0.036) ( Table 2). This may be in part due to the fact that coronavirus might also use different receptors to enter the host cell and the possible effects of statins only via inhibition of special receptors such as LDL-receptors (LDL-R), resulting in there are conflicting results regarding the effects between statins therapy and dyslipidemia on the COVID-19 [28,29]. Furthermore, it has been suggested that statins act differently in ARDS patients at different status (hyper-inflammatory vs. hypo-inflammatory) [30].…”

Section: Discussionmentioning

confidence: 99%

Altered Lipid Profile is a Risk Factor for the Progression Andrecurrenceof COVID-19: From Two Retrospective Cohorts

Jin¹,

He²,

Dong³

et al. 2020

Preprint

View full text Add to dashboard Cite

Background The COVID-19 pandemic has spread worldwide. However, the impact of lipid profile and lipid-lowering treatment on clinical endpoints in COVID-19 have not previously been investigated. Methods In this retrospective, multicenter cohort study, we consecutively enrolled 430 adult COVID-19 patients from two Chinese hospitals (one each in Chengdu and Wuhan) admitted during February 2020 and followed-up until April 30. Demographic, metabolic profile, laboratory, treatment and clinical endpoint data including in-hospital death and recurrence of COVID-19, were collected. Results In Chengdu patients, univariable and multivariable Cox regression showed that the low-density lipoprotein cholesterol (LDL-C) dyslipidemia on admission was associated with the recurrence of COVID-19 during the follow-up period. In Wuhan cohort, the patients with triglycerides hyperlipemia had an increased risk of in-hospital death. However, in both cohorts, statin therapy during COVID-19 course did not affect these clinical endpoints. Compared to the Chengdu cohort, the Wuhan patients tended to have more severe COVID-19 but, unexpectedly, had lower levels of serum lipid. It is of interesting to notice that the relationship between the observed biomarkers of inflammation and lipid do not match the relationship between the organ function measures and this lipid. Conclusions The baseline dyslipidemia should be considered as a risk factor for poor prognosis and recurrence of COVID-19. The lipid level may be altered during COVID-19 course, since lipidology may be distinctly affected by both inflammation and organic damage for SARS-CoV-2. Further investigation is needed on the role of use of lipid-lowering therapy among patients with COVID-19 infections.

show abstract

“…In patients with CVD their usage should not be discontinued. However, it remains unclear whether starting these medications prophylactically or during COVID-19 has any clinical benefit ( Banach et al, 2020 ; Katsiki et al, 2020 ; Reiner et al, 2020 ).…”

Section: Perspective and Future Directionsmentioning

confidence: 99%

Pathophysiology of Cardiovascular Complications in COVID-19

Petrović

Radenković

et al. 2020

Front. Physiol.

Self Cite

View full text Add to dashboard Cite

Numerous recent studies have shown that patients with underlying cardiovascular disease (CVD) are at increased risk of more severe clinical course as well as mortality of COVID-19. Also, the available data suggests that COVID-19 is related to numerous de novo cardiovascular complications especially in the older population and those with pre-existing chronic cardiometabolic conditions. SARS-CoV-2 virus can cause acute cardiovascular injury, as well as increase the risk of chronic cardiovascular damage. As CVD seem to be the major comorbidity in critically unwell patients with COVID-19 and patients often die of cardiovascular complications, we review the literature and discuss the possible pathophysiology and molecular pathways driving these disease processes: cytokine release syndrome, RAAS system dysregulation, plaque destabilization and coagulation disorders with the aim to identify novel treatment targets. In addition, we review the pediatric population, the major cause of the cardiovascular complications is pediatric inflammatory multisystem syndrome that is believed to be associated with COVID-19 infection. Due to the increasingly recognized CVD damage in COVID-19, there is a need to establish clear clinical and follow-up protocols and to identify and treat possible comorbidities that may be risk factors for the development of cardiovascular complications.

show abstract

Lipid-lowering therapy and renin-angiotensin-aldosterone system inhibitors in the era of the COVID-19 pandemic

Cited by 79 publications

References 60 publications

Commentary: Statins, COVID-19, and coronary artery disease: killing two birds with one stone

Commentary: Statins, COVID-19, and coronary artery disease: killing two birds with one stone

Altered Lipid Profile is a Risk Factor for the Progression Andrecurrenceof COVID-19: From Two Retrospective Cohorts

Pathophysiology of Cardiovascular Complications in COVID-19

Contact Info

Product

Resources

About